Monthly Archives: December 2017
CAR T-Cell Therapy HCP Guide – Challenges: Car-T and Solid Tumors
The Challenging Solid Tumor Microenvironment
The challenging tumor microenvironment is another obstacle with CAR T-cell therapy of solid tumors.
As reported by Newick and colleagues,...
‘Synthetic gene circuit’ may improve effectiveness of cancer immunotherapy
October 19, 2017 (Medical News Today)
Immunotherapy, which activates a patient’s own immune system to attack cancer, is still a new approach to treating...
CAR T-Cell Therapy HCP Guide – Solid Tumors
Solid Tumor Research: Ongoing
CAR T-cell therapy has shown great success in hematologic malignancies, such as non-Hodgkin's lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular...
CAR T-Cell Therapy HCP Guide – Efficacy and Safety of Zuma Trials
ZUMA-3 and ZUMA-4 Trials
In addition to the October 2017 approval for Non-Hodgkin lymphoma, Yescarta (axicabtagene ciloleucel) has shown impressive early results in difficult-to-treat patients...
